Ondansetron in the treatment of panic disorder

Anxiety

Volumn 2, Issue 4, 1996, Pages 199-202

  Schneier, Franklin R ^a,c   Garfinkel, Robin ^a   Kennedy, Barbara ^b   Campeas, Raphael ^a   Fallon, Brian ^a   Marshall, Randall ^a   O'Donnell, Lisa ^a   Hogan, Tony ^b   Liebowitz, Michael R ^a  

^a The New York Presbyterian Hospital   (United States)

^b University of Louisville School of Medicine   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Anxiety; Anxiolytics; Ondansetron; Panic disorder; Psychopharmacology

Indexed keywords

ONDANSETRON;

ADULT; AGORAPHOBIA; ARTICLE; FEMALE; HUMAN; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PANIC; PERSONALITY TEST; PHOBIA; PILOT STUDY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGORAPHOBIA; FEMALE; HUMANS; MALE; MIDDLE AGED; ONDANSETRON; PANIC DISORDER; PERSONALITY INVENTORY; PHOBIC DISORDERS; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0030325717     PISSN: 10709797     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-7154(1996)2:4<199::AID-ANXI7>3.0.CO;2-J     Document Type: Article

References (15)

1. Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB (1988) Pharmacological properties of GR 38032F, a novel antagonist at 5-HT, receptors. Br J Pharmacol 94:397-412.
2. Derogatis LR (1977) SCL-90 Administration, Scoring and Procedures Manual for the Revised Version. Baltimore: Johns Hopkins University School of Medicine.
3. Fyer AJ, Liebowitz MR, Gorman JM, Campeas R, Levin A, Davies SO, Goetz D, Klein DF (1987) Discontinuation of alprazolam treatment in panic patients. Am J Psychiatry 143:303-308.
4. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, Klein DF (1987) An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 7:329-332.
5. Guy W (1976) ECDEU Assessment Manual of Psychopharmacology. Washington, DC: DHEW.
6. Hall ST, Ceuppens PR (1991) A study to evaluate the effect of ondansetron on psychomotor performance after repeated oral dosing in healthy subjects. Psychopharmacol 104:86-90.
7. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
8. Marks IM, Mathews AM (1979) Brief standard self-rating scale for phobic patients. Behav Res Ther 14:225-238.
9. Noyes R Jr, Garvey MJ, Cook BL, Samuelson L (1989) Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: Results of a naturalistic follow-up study. J Clin Psychiatry 50:163-169.
10. Reiss S, Peterson RA, Gursky DM, McNally RJ (1986) Anxiety sensitivity, anxiety frequency, and the prediction of fearfulness. Behav Res Ther 24:1-8.
11. Shear MK, Maser JD (1994) Standardized assessment for panic disorder research. Arch Gen Psychiatry 51:346-354.
12. Sheehan J (1983) The Anxiety Disease. New York: Harper & Row.
13. Spitzer RL, Williams JBW, Gibbon M, First MB (1989) Structured Clinical Interview for DSM-III-R-Patient Version (SCID-P). New York: New York State Psychiatric Institute, Biometrics Research.
14. Stefanski R, Palejko W, Kostowski W, Plaznik A (1992) The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology 31:1251-1258.
15. Zitrin CM, Klein DF, Woerner MG, Ross DC (1983) Treatment of phobias. I. Comparison of imipramine and placebo. Arch Gen Psychiatry 40:125-138.